genome research limited
genome research limited Company Information
Company Number
02742969
Website
http://www.sanger.ac.ukRegistered Address
wellcome sanger institute, wellcome genome campus, saffron walden, CB10 1SA
Industry
Research and experimental development on biotechnology
Telephone
01223834244
Next Accounts Due
June 2025
Group Structure
View All
Shareholders
-0%
genome research limited Estimated Valuation
Pomanda estimates the enterprise value of GENOME RESEARCH LIMITED at £463.9m based on a Turnover of £189m and 2.45x industry multiple (adjusted for size and gross margin).
genome research limited Estimated Valuation
Pomanda estimates the enterprise value of GENOME RESEARCH LIMITED at £219m based on an EBITDA of £21.1m and a 10.37x industry multiple (adjusted for size and gross margin).
genome research limited Estimated Valuation
Pomanda estimates the enterprise value of GENOME RESEARCH LIMITED at £584.1m based on Net Assets of £271.6m and 2.15x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Genome Research Limited Overview
Genome Research Limited is a live company located in saffron walden, CB10 1SA with a Companies House number of 02742969. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in August 1992, it's largest shareholder is unknown. Genome Research Limited is a mature, mega sized company, Pomanda has estimated its turnover at £189m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Genome Research Limited Health Check
Pomanda's financial health check has awarded Genome Research Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 3 areas for improvement. Company Health Check FAQs
7 Strong
2 Regular
3 Weak
Size
annual sales of £189m, make it larger than the average company (£3.6m)
£189m - Genome Research Limited
£3.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 7%, show it is growing at a slower rate (11.8%)
7% - Genome Research Limited
11.8% - Industry AVG
Production
with a gross margin of 53.5%, this company has a comparable cost of product (53.5%)
53.5% - Genome Research Limited
53.5% - Industry AVG
Profitability
an operating margin of 4.5% make it more profitable than the average company (-0.1%)
4.5% - Genome Research Limited
-0.1% - Industry AVG
Employees
with 1209 employees, this is above the industry average (46)
1209 - Genome Research Limited
46 - Industry AVG
Pay Structure
on an average salary of £68.9k, the company has an equivalent pay structure (£77k)
£68.9k - Genome Research Limited
£77k - Industry AVG
Efficiency
resulting in sales per employee of £156.4k, this is more efficient (£131.1k)
£156.4k - Genome Research Limited
£131.1k - Industry AVG
Debtor Days
it gets paid by customers after 11 days, this is earlier than average (52 days)
11 days - Genome Research Limited
52 days - Industry AVG
Creditor Days
its suppliers are paid after 26 days, this is quicker than average (70 days)
26 days - Genome Research Limited
70 days - Industry AVG
Stock Days
it holds stock equivalent to 20 days, this is less than average (50 days)
20 days - Genome Research Limited
50 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 15 weeks, this is less cash available to meet short term requirements (35 weeks)
15 weeks - Genome Research Limited
35 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 21.8%, this is a lower level of debt than the average (50%)
21.8% - Genome Research Limited
50% - Industry AVG
GENOME RESEARCH LIMITED financials
Genome Research Limited's latest turnover from September 2023 is £189 million and the company has net assets of £271.6 million. According to their latest financial statements, Genome Research Limited has 1,209 employees and maintains cash reserves of £13.8 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 189,031,000 | 185,940,000 | 221,458,000 | 156,394,000 | 152,373,000 | 144,812,000 | 135,336,000 | 125,064,000 | 145,703,000 | 119,484,000 | 113,993,000 | 101,492,000 | 100,772,000 | 93,920,000 | 96,221,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-Tax Profit | 6,766,000 | 3,462,000 | 13,650,000 | -15,483,000 | -13,491,000 | -2,454,000 | -8,604,000 | -6,102,000 | 15,967,000 | 4,929,000 | -1,455,000 | -6,132,000 | -3,305,000 | -3,206,000 | -5,607,000 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3,160,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 6,766,000 | 3,462,000 | 13,650,000 | -15,483,000 | -13,491,000 | -2,454,000 | -8,604,000 | -6,102,000 | 12,807,000 | 4,929,000 | -1,455,000 | -6,132,000 | -3,305,000 | -3,206,000 | -5,607,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 6,766,000 | 3,462,000 | 13,650,000 | -15,483,000 | -13,491,000 | -2,454,000 | -8,604,000 | -6,102,000 | 12,807,000 | 4,929,000 | -1,455,000 | -6,132,000 | -3,305,000 | -3,206,000 | -5,607,000 |
| Employee Costs | 83,360,000 | 73,144,000 | 71,940,000 | 74,987,000 | 71,477,000 | 69,827,000 | 72,982,000 | 61,499,000 | 54,311,000 | 48,612,000 | 46,322,000 | 42,027,000 | 40,332,000 | 38,247,000 | 36,989,000 |
| Number Of Employees | 1,209 | 1,114 | 1,178 | 1,055 | 1,073 | 1,070 | 1,075 | 1,015 | 1,006 | 956 | 902 | 852 | 839 | 838 | 822 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 172,518,000 | 162,440,000 | 167,864,000 | 160,627,000 | 165,945,000 | 167,038,000 | 163,569,000 | 163,091,000 | 156,074,000 | 131,673,000 | 124,348,000 | 109,098,000 | 109,880,000 | 110,886,000 | 110,593,000 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 89,061,000 | 18,780,000 | 4,398,000 | 4,331,000 | 4,331,000 | 5,921,000 | 4,484,000 | 1,951,000 | 871,000 | 2,000 | 2,000 | 2,000 | 2,000 | 1,000 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 261,579,000 | 181,220,000 | 172,262,000 | 164,958,000 | 170,276,000 | 172,959,000 | 168,053,000 | 165,042,000 | 156,945,000 | 131,675,000 | 124,350,000 | 109,100,000 | 109,882,000 | 110,887,000 | 110,593,000 |
| Stock & work in progress | 4,963,000 | 9,841,000 | 13,681,000 | 10,894,000 | 9,472,000 | 6,086,000 | 2,079,000 | 2,084,000 | 2,657,000 | 2,195,000 | 2,264,000 | 3,080,000 | 3,570,000 | 2,958,000 | 2,717,000 |
| Trade Debtors | 6,056,000 | 2,781,000 | 11,876,000 | 3,987,000 | 2,844,000 | 8,942,000 | 18,343,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 45,924,000 | 48,001,000 | 36,618,000 | 24,584,000 | 14,820,000 | 12,722,000 | 10,584,000 | 18,349,000 | 8,436,000 | 2,071,000 | 1,437,000 | 264,000 | 5,971,000 | 10,139,000 | 4,969,000 |
| Misc Debtors | 15,058,000 | 16,217,000 | 12,645,000 | 18,255,000 | 19,241,000 | 10,141,000 | 10,089,000 | 17,022,000 | 27,723,000 | 11,747,000 | 8,913,000 | 9,307,000 | 9,666,000 | 7,231,000 | 8,805,000 |
| Cash | 13,809,000 | 7,516,000 | 4,629,000 | 10,461,000 | 27,180,000 | 1,995,000 | 4,663,000 | 2,180,000 | 5,562,000 | 4,767,000 | 6,874,000 | 5,762,000 | 4,493,000 | 5,121,000 | 3,216,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 85,810,000 | 84,356,000 | 79,449,000 | 68,181,000 | 73,557,000 | 39,886,000 | 45,758,000 | 39,635,000 | 44,378,000 | 20,780,000 | 19,488,000 | 18,413,000 | 23,700,000 | 25,449,000 | 19,707,000 |
| total assets | 347,389,000 | 265,576,000 | 251,711,000 | 233,139,000 | 243,833,000 | 212,845,000 | 213,811,000 | 204,677,000 | 201,323,000 | 152,455,000 | 143,838,000 | 127,513,000 | 133,582,000 | 136,336,000 | 130,300,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 6,271,000 | 4,524,000 | 15,461,000 | 3,545,000 | 14,685,000 | 5,131,000 | 5,736,000 | 6,521,000 | 2,663,000 | 2,653,000 | 5,288,000 | 2,309,000 | 7,115,000 | 7,029,000 | 4,551,000 |
| Group/Directors Accounts | 1,798,000 | 622,000 | 0 | 0 | 0 | 0 | 0 | 1,659,000 | 710,000 | 8,870,000 | 4,968,000 | 7,006,000 | 4,893,000 | 4,022,000 | 2,647,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 37,031,000 | 43,634,000 | 37,911,000 | 45,928,000 | 40,207,000 | 13,011,000 | 23,008,000 | 17,116,000 | 16,780,000 | 9,667,000 | 9,610,000 | 7,198,000 | 9,792,000 | 12,498,000 | 9,509,000 |
| total current liabilities | 45,100,000 | 48,780,000 | 53,372,000 | 49,473,000 | 54,892,000 | 18,142,000 | 28,744,000 | 25,296,000 | 20,153,000 | 21,190,000 | 19,866,000 | 16,513,000 | 21,800,000 | 23,549,000 | 16,707,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,900,000 | 1,900,000 | 1,900,000 | 3,000,000 |
| hp & lease commitments | 27,300,000 | 17,224,000 | 16,633,000 | 17,165,000 | 17,698,000 | 21,924,000 | 19,895,000 | 18,838,000 | 18,605,000 | 18,541,000 | 16,677,000 | 3,350,000 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 3,430,000 | 3,079,000 | 5,375,000 | 5,520,000 | 6,879,000 | 3,324,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 30,730,000 | 20,303,000 | 155,208,000 | 221,485,000 | 227,577,000 | 139,148,000 | 154,895,000 | 221,838,000 | 120,805,000 | 99,041,000 | 72,777,000 | 46,350,000 | 42,400,000 | 48,100,000 | 43,200,000 |
| total liabilities | 75,830,000 | 69,083,000 | 208,580,000 | 270,958,000 | 282,469,000 | 157,290,000 | 183,639,000 | 247,134,000 | 140,958,000 | 120,231,000 | 92,643,000 | 62,863,000 | 64,200,000 | 71,649,000 | 59,907,000 |
| net assets | 271,559,000 | 196,493,000 | 43,131,000 | -37,819,000 | -38,636,000 | 55,555,000 | 30,172,000 | -42,457,000 | 60,365,000 | 32,224,000 | 51,195,000 | 64,650,000 | 69,382,000 | 64,687,000 | 70,393,000 |
| total shareholders funds | 271,559,000 | 196,493,000 | 43,131,000 | -37,819,000 | -38,636,000 | 55,555,000 | 30,172,000 | -42,457,000 | 60,365,000 | 32,224,000 | 51,195,000 | 64,650,000 | 69,382,000 | 64,687,000 | 70,393,000 |
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 12,626,000 | 14,276,000 | 14,179,000 | 14,091,000 | 11,952,000 | 10,673,000 | 12,058,000 | 12,437,000 | 12,598,000 | 11,282,000 | 13,471,000 | 13,941,000 | 13,783,000 | 12,398,000 | 13,480,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3,160,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | -4,878,000 | -3,840,000 | 2,787,000 | 1,422,000 | 3,386,000 | 4,007,000 | -5,000 | -573,000 | 462,000 | -69,000 | -816,000 | -490,000 | 612,000 | 241,000 | 2,717,000 |
| Debtors | 39,000 | 5,860,000 | 14,313,000 | 9,921,000 | 5,100,000 | -7,211,000 | 3,645,000 | -788,000 | 22,341,000 | 3,468,000 | 779,000 | -6,066,000 | -1,733,000 | 3,596,000 | 13,774,000 |
| Creditors | 1,747,000 | -10,937,000 | 11,916,000 | -11,140,000 | 9,554,000 | -605,000 | -785,000 | 3,858,000 | 10,000 | -2,635,000 | 2,979,000 | -4,806,000 | 86,000 | 2,478,000 | 4,551,000 |
| Accruals and Deferred Income | -6,603,000 | 5,723,000 | -8,017,000 | 5,721,000 | 27,196,000 | -9,997,000 | 5,892,000 | 336,000 | 7,113,000 | 57,000 | 2,412,000 | -2,594,000 | -2,706,000 | 2,989,000 | 9,509,000 |
| Deferred Taxes & Provisions | 351,000 | -2,296,000 | -145,000 | -1,359,000 | 3,555,000 | 3,324,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | -36,813,000 | -18,627,000 | -11,326,000 | -9,514,000 | -10,062,000 | -12,929,000 | -10,630,000 | ||||||||
| Change in Investments | 70,281,000 | 14,382,000 | 67,000 | 0 | -1,590,000 | 1,437,000 | 2,533,000 | 1,080,000 | 869,000 | 0 | 0 | 0 | 1,000 | 1,000 | 0 |
| cash flow from investments | -37,682,000 | -18,627,000 | -11,326,000 | -9,514,000 | -10,063,000 | -12,930,000 | -10,630,000 | ||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 1,176,000 | 622,000 | 0 | 0 | 0 | 0 | -1,659,000 | 949,000 | -8,160,000 | 3,902,000 | -2,038,000 | 2,113,000 | 871,000 | 1,375,000 | 2,647,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,900,000 | 0 | 0 | -1,100,000 | 3,000,000 |
| Hire Purchase and Lease Commitments | 10,076,000 | 591,000 | -532,000 | -533,000 | -4,226,000 | 2,029,000 | 1,057,000 | 233,000 | 64,000 | 1,864,000 | 13,327,000 | 3,350,000 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from financing | 79,552,000 | 151,113,000 | 66,768,000 | 15,767,000 | -84,926,000 | 29,866,000 | 80,631,000 | -95,538,000 | 7,238,000 | -18,134,000 | -2,611,000 | 6,863,000 | 8,871,000 | -2,225,000 | 81,647,000 |
| cash and cash equivalents | |||||||||||||||
| cash | 6,293,000 | 2,887,000 | -5,832,000 | -16,719,000 | 25,185,000 | -2,668,000 | 2,483,000 | -3,382,000 | 795,000 | -2,107,000 | 1,112,000 | 1,269,000 | -628,000 | 1,905,000 | 3,216,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 6,293,000 | 2,887,000 | -5,832,000 | -16,719,000 | 25,185,000 | -2,668,000 | 2,483,000 | -3,382,000 | 795,000 | -2,107,000 | 1,112,000 | 1,269,000 | -628,000 | 1,905,000 | 3,216,000 |
genome research limited Credit Report and Business Information
Genome Research Limited Competitor Analysis
Perform a competitor analysis for genome research limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
genome research limited Ownership
GENOME RESEARCH LIMITED group structure
Genome Research Limited has 4 subsidiary companies.
Ultimate parent company
1 parent
GENOME RESEARCH LIMITED
02742969
4 subsidiaries
genome research limited directors
Genome Research Limited currently has 11 directors. The longest serving directors include Mrs Kathy Poole (May 2019) and Dr Nicole Mather (Jul 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mrs Kathy Poole | England | 60 years | May 2019 | - | Director |
| Dr Nicole Mather | England | 49 years | Jul 2019 | - | Director |
| Dr Paul Schreier | 55 years | Oct 2019 | - | Director | |
| Mr Daniel Abrams | England | 68 years | Dec 2019 | - | Director |
| Dame Cilla Snowball | England | 65 years | Jan 2020 | - | Director |
| Dr Daniel Mahony | England | 55 years | Mar 2020 | - | Director |
| Mr Matthew Newcombe-Ellis | England | 38 years | Mar 2024 | - | Director |
| Ms Caroline Relton | England | 56 years | Mar 2024 | - | Director |
| Ms Karen Chadwick | England | 57 years | Mar 2024 | - | Director |
| Mr Mark McCarthy | England | 63 years | Mar 2024 | - | Director |
P&L
September 2023turnover
189m
+2%
operating profit
8.5m
0%
gross margin
53.6%
+1.04%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
September 2023net assets
271.6m
+0.38%
total assets
347.4m
+0.31%
cash
13.8m
+0.84%
net assets
Total assets minus all liabilities
Similar Companies
genome research limited company details
company number
02742969
Type
Private Ltd By Guarantee w/o Share Cap
industry
72110 - Research and experimental development on biotechnology
incorporation date
August 1992
age
32
accounts
Full Accounts
ultimate parent company
previous names
N/A
incorporated
UK
address
wellcome sanger institute, wellcome genome campus, saffron walden, CB10 1SA
last accounts submitted
September 2023
genome research limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to genome research limited.
genome research limited Companies House Filings - See Documents
| date | description | view/download |
|---|
